Trial Profile
A Phase 1, Open-Label, Randomized, Single Dose, 3-Way Crossover Study to Address the Relative Bioavailability of Solifenacin Liquid Suspension 10mg (Fed and Fasting) Versus the VESIcare (Solifenacin Succinate) 10 mg Tablet (Fasting) in Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Dec 2009
Price :
$35
*
At a glance
- Drugs Solifenacin (Primary)
- Indications Overactive bladder
- Focus Pharmacokinetics
- Sponsors Astellas Pharma
- 11 Dec 2009 Status changed from active, no longer recruiting to completed.
- 21 Nov 2009 New trial record